[an error occurred while processing this directive]
中华放射肿瘤学杂志
   2025年4月7日 星期一     首 页 |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告合作  |  学术影响  |  收录情况  |  联系我们  |  English
中华放射肿瘤学杂志  2021, Vol. 30 Issue (1): 66-70    DOI: 10.3760/cma.j.cn113030-20200324-00131
腹部肿瘤 最新目录| 下期目录| 过刊浏览| 高级检索 [an error occurred while processing this directive]|[an error occurred while processing this directive]
PEG-rhG-CSF初级预防同步放化疗后中性粒细胞减少的有效性观察
陈扬, 王巍, 张瑞平, 刘冉生, 张爱旭, 王志震
天津医科大学肿瘤医院肿瘤研究所放疗科国家肿瘤临床医学研究中心 天津市肿瘤防治重点实验室 天津市恶性肿瘤临床医学研究中心 300060
Efficacy of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) therapy in the primary prevention of concurrent chemoradiotherapy-induced neutropenia
Chen Yang, Wang Wei, Zhang Ruiping, Liu Ransheng, Zhang Aixu, Wang Zhizhen
Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer;Key Laboratory of Cancer Prevention and Therapy of Tianjin;Tianjin's Clinical Research Center for Cancer;Tianjin 300060, China
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      背景资料
摘要 目的 评价聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)初级预防同步放化疗后中性粒细胞减少的有效性。方法 开放、单臂临床观察天津医科大学肿瘤医院2018—2019年行同步放化疗的58例患者采用PEG-rhG-CSF初级预防同步放化疗后中性粒细胞减少的有效性。结果 整个同步放化疗周期期间化疗延迟6例(10%),其中因白细胞或中性粒细胞减少导致化疗延迟3例(5%),化疗周期完成率为94.6%(106/112);放疗延迟10例(17%),其中因白细胞或中性粒细胞减少导致放疗延迟2例(3%)。中性粒细胞减少性发热(FN)发生率为0。亚组分析发现同步完成1周期化疗后,4级白细胞减少、中性粒细胞减少发生率均为0%;同步完成2周期化疗后4级白细胞减少、中性粒细胞减少发生率分别为0、2%。结论 同步放化疗期间应用PEG-rhG-CSF初级预防可有效降低FN及4级白细胞、中性粒细胞减少发生率,利于同步放化疗顺利进行。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
陈扬
王巍
张瑞平
刘冉生
张爱旭
王志震
关键词 聚乙二醇化重组人粒细胞集落刺激因子初级预防同步放化疗中性粒细胞减少    
AbstractObjective To evaluate the efficacy and safety of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) therapy in the primary prevention of concurrent chemoradiotherapy-induced neutropenia. Methods In this single-center, open-label, single-arm clinical observation, the efficacy of PEG-rhG-CSF in the primary prevention of neutropenia after concurrent chemoradiotherapy in 58 patients admitted to Tianjin Medical University Cancer Institute and Hospital from June 2018 to June 2019 was evaluated. Results During the whole concurrent chemoradiotherapy, chemotherapy delay occurred in 6 patients (10%). Three patients (5%) had delayed concurrent chemotherapy due to leukopenia or neutropenia. The completion rate of chemotherapy cycle was 94.6%(106/112). Radiotherapy delay occurred in 10 patients (17%) including 2 patients (3%) of delayed radiotherapy due to leukopenia or neutropenia. No patient developed febrile neutropenia (FN). Subgroup analysis found that after completing 1 cycle of concurrent chemoradiotherapy, the incidence rates of grade 4 leukopenia and neutropenia were both 0. After completing 2 cycles of concurrent chemoradiotherapy, the incidence rates of grade 4 leukopenia and neutropenia were 0 and 2%. Conclusion During the chemoradiotherapy, application of PEG-rhG-CSF in the primary preventation can significantly reduce the incidence of FN, grade 4 leukopenia and neutropenia, which is beneficial to ensure the smooth progress of concurrent chemoradiotherapy.
Key wordsPEG-rhG-CSF    Primary prevention    Concurrent chemoradiotherapy    Neutropenia   
收稿日期: 2020-03-24     
通讯作者: 王志震,Email:965458069@qq.com   
引用本文:   
陈扬,王巍,张瑞平等. PEG-rhG-CSF初级预防同步放化疗后中性粒细胞减少的有效性观察[J]. 中华放射肿瘤学杂志, 2021, 30(1): 66-70.
Chen Yang,Wang Wei,Zhang Ruiping et al. Efficacy of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) therapy in the primary prevention of concurrent chemoradiotherapy-induced neutropenia[J]. Chinese Journal of Radiation Oncology, 2021, 30(1): 66-70.
链接本文:  
http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20200324-00131     或     http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2021/V30/I1/66
京公网安备11010502022167号
版权所有 © 2010《中华放射肿瘤学杂志》编辑部
地址:北京朝阳区潘学园南里17号 中国医学科学院肿瘤医院(100021)
电话:010-67700737,87788294 Email: cjron@cmaph.org
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:Support@magtech.com.cn